MDT

101.85

+2.05%↑

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

MDT

101.85

+2.05%↑

139.48

+1.36%↑

VEEV

222.48

+1.7%↑

HQY

87.09

+2.94%↑

NEOG

9.97

+3.96%↑

Начало・Списък с акции・MediciNova Inc

MediciNova Inc

Отворен

СекторЗдравеопазване

1.67 0.6

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.6400000000000001

Максимум

1.6800000000000002

Ключови измерители
By Trading Economics
Приходи	6.1B -3.1M
Продажби	-11K 123K
EPS	-0.06
Марж на печалбата	-2,473.563
Служители	13
EBITDA	599K -3M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+554.76% upside

Дивиденти
By Dow Jones
Следващи печалби	17.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	9.5M 79M
Предишно отваряне	1.07
Предишно затваряне	1.67

Настроения в новините

By Acuity

56%

44%

309 / 360 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

1.48 / 1.5599 Подкрепа & съпротива

MediciNova Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.01.2026 г., 23:49 ч. UTC

Значими двигатели на пазара

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21.01.2026 г., 21:12 ч. UTC

Значими двигатели на пазара

Automaker Stocks Rise After Trump Calls Off European Tariffs

21.01.2026 г., 21:00 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21.01.2026 г., 20:29 ч. UTC

Значими двигатели на пазара

Chip Makers Gain After Trump Calls Off European Tariffs

21.01.2026 г., 20:04 ч. UTC

Значими двигатели на пазара

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21.01.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21.01.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21.01.2026 г., 22:39 ч. UTC

Печалби

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

21.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.01.2026 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21.01.2026 г., 21:19 ч. UTC

Печалби

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21.01.2026 г., 20:45 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Borse Group to Acquire Allfunds for $6.19B

21.01.2026 г., 20:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21.01.2026 г., 20:31 ч. UTC

Пазарно говорене

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21.01.2026 г., 20:27 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21.01.2026 г., 20:27 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.01.2026 г., 20:27 ч. UTC

Пазарно говорене

Was It a 'TACO' Event? -- Market Talk

21.01.2026 г., 20:26 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21.01.2026 г., 20:23 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21.01.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21.01.2026 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Deutsche Boerse Group Agrees to Buy Allfunds

21.01.2026 г., 20:08 ч. UTC

Печалби

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21.01.2026 г., 20:03 ч. UTC

Пазарно говорене

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21.01.2026 г., 19:51 ч. UTC

Пазарно говорене

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21.01.2026 г., 19:43 ч. UTC

Пазарно говорене

U.S. Ethanol Production Expected to Slip -- Market Talk

21.01.2026 г., 19:31 ч. UTC

Пазарно говорене

Gold Settles at Fresh All-Time High -- Market Talk

21.01.2026 г., 19:24 ч. UTC

Печалби

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21.01.2026 г., 19:10 ч. UTC

Пазарно говорене

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21.01.2026 г., 18:57 ч. UTC

Пазарно говорене

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

MediciNova Inc Прогноза

Ценова цел

By TipRanks

554.76% нагоре

12-месечна прогноза

Среден 11 USD 554.76%

Висок 11 USD

Нисък 11 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за MediciNova Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на MediciNova Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.48 / 1.5599Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

309 / 360 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MediciNova Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.